US 11,951,214 B2
Capsule formulations
Manmohan Reddy Leleti, Dublin, CA (US); and Jay P. Powers, Pacifica, CA (US)
Assigned to CHEMOCENTRYX, INC., Thousand Oaks, CA (US)
Filed by CHEMOCENTRYX, INC., San Carlos, CA (US)
Filed on Dec. 8, 2021, as Appl. No. 17/545,878.
Application 17/545,878 is a continuation of application No. 16/697,523, filed on Nov. 27, 2019, abandoned.
Claims priority of provisional application 62/773,848, filed on Nov. 30, 2018.
Prior Publication US 2022/0233453 A1, Jul. 28, 2022
Int. Cl. A61K 9/48 (2006.01); A61K 31/4412 (2006.01)
CPC A61K 9/4858 (2013.01) [A61K 9/4808 (2013.01); A61K 9/4825 (2013.01); A61K 9/4833 (2013.01); A61K 31/4412 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A solid solution capsule formulation comprising Compound 1 as a free base, in its neutral form, or in the form of a pharmaceutically acceptable salt

OG Complex Work Unit Chemistry
and a vehicle comprising
at least one non-ionic surfactant selected from the group consisting of macrogol-40-glycerol hydroxystearate, macrogolglycerol ricinoleate, and macrogol-15-hydroxystearate, and
at least one water-soluble solubilizer selected from the group consisting of PEG-1500, PEG-1540, PEG-2000, PEG-3000, PEG-3350, PEG-4000, PEG-6000, PEG-8000,
wherein
Compound 1 comprises about 1 to 3% by weight of the total fill weight of said solid solution capsule formulation, the vehicle comprises about 97 to 99% by weight of the total fill weight of said solid solution capsule formulation, and
the total weight of the vehicle comprises a 45:55 to 55:45 ratio of the at least one non-ionic surfactant to the at least one water-soluble solubilizer.